OBJECTIVES/HYPOTHESIS: To determine the prognostic influence of p16(INK4a) immunohistochemistry on the survival of resectable oropharyngeal carcinomas (OPSCC). STUDY DESIGN: Retrospective pathologic evaluation of a prospective single-arm cohort study at a tertiary referral center. METHODS: There were 48 patients with resectable OPSCC who consented for transoral robotic surgery (TORS) and banked tissue specimen for assessment. TORS was with or without adjuvant radiation or chemoradiation. Main outcome measures were p16(INK4a) status, human papillomavirus status, local-regional disease control, and overall, disease-specific, and disease-free survival. RESULTS: p16(INK4a) and HPV positivity were identified in 73% and 74% of patients respectively. With a median follow-up of 38.8 months (2.5-63.3 months), only one local-regional relapse has occurred in both the p16(INK4a)-positive and p16(INK4a) -negative cohorts. No disease-specific, disease-free, and overall survival differences were observed between p16(INK4a) -positive and p16(INK4a)-negative patients (P = .446, P = .277, P = .643, respectively). CONCLUSIONS: p16(INK4a) was not prognostic in resectable OPSCC when treated with an initial TORS approach.
OBJECTIVES/HYPOTHESIS: To determine the prognostic influence of p16(INK4a) immunohistochemistry on the survival of resectable oropharyngeal carcinomas (OPSCC). STUDY DESIGN: Retrospective pathologic evaluation of a prospective single-arm cohort study at a tertiary referral center. METHODS: There were 48 patients with resectable OPSCC who consented for transoral robotic surgery (TORS) and banked tissue specimen for assessment. TORS was with or without adjuvant radiation or chemoradiation. Main outcome measures were p16(INK4a) status, human papillomavirus status, local-regional disease control, and overall, disease-specific, and disease-free survival. RESULTS:p16(INK4a) and HPV positivity were identified in 73% and 74% of patients respectively. With a median follow-up of 38.8 months (2.5-63.3 months), only one local-regional relapse has occurred in both the p16(INK4a)-positive and p16(INK4a) -negative cohorts. No disease-specific, disease-free, and overall survival differences were observed between p16(INK4a) -positive and p16(INK4a)-negative patients (P = .446, P = .277, P = .643, respectively). CONCLUSIONS:p16(INK4a) was not prognostic in resectable OPSCC when treated with an initial TORS approach.
Authors: Dana M Hartl; Daniel F Brasnu; Jatin P Shah; Michael L Hinni; Robert P Takes; Kerry D Olsen; Luiz P Kowalski; Juan P Rodrigo; Primož Strojan; Gregory T Wolf; Alessandra Rinaldo; Carlos Suárez; William M Mendenhall; Vinidh Paleri; Arlene A Forastiere; Jochen A Werner; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2013-01-03 Impact factor: 2.503
Authors: Georgios Psychogios; Christoph Alexiou; Abba Agaimy; Kathrin Brunner; Michael Koch; Konstantinos Mantsopoulos; Andrea Tomppert; Heinrich Iro Journal: Cancer Med Date: 2014-03-10 Impact factor: 4.452
Authors: C Grønhøj Larsen; M Gyldenløve; D H Jensen; M H Therkildsen; K Kiss; B Norrild; L Konge; C von Buchwald Journal: Br J Cancer Date: 2014-02-11 Impact factor: 7.640